A double-blind comparative multicenter study of the efficacy and safety of parecoxib IV/IM [intravenous/intramuscular] 40 mg vs placebo on reducing opioids consumption following sub muscular breast augmentation surgery.

Trial Profile

A double-blind comparative multicenter study of the efficacy and safety of parecoxib IV/IM [intravenous/intramuscular] 40 mg vs placebo on reducing opioids consumption following sub muscular breast augmentation surgery.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 13 Mar 2012

At a glance

  • Drugs Parecoxib; Parecoxib
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Mar 2012 Location (Peru) added as reported by ClinicalTrials.gov.
    • 02 Nov 2007 Status changed from initiated to withdrawn prior to recruitment.
    • 17 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top